Janux Therapeutics
↗San Diego, California, USA
Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered novel T cell immunotherapies for cancer and autoimmune disease treatment. Founded in 2017 by David Campbell, the company specializes in selectively modulating T cells to overcome traditional safety limitations of contemporary immunotherapies. Janux utilizes proprietary technology platforms—TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator)—to engineer next-generation drug candidates that combine tumor antigen-binding domains with T cell activation domains, enabling targeted cancer cell destruction while minimizing systemic toxicity. The company has demonstrated promising early clinical activity with its lead programs and has established a significant strategic partnership with global pharmaceutical leader Merck.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology biotech | Autoimmune disease therapeutics
SIZE & FINANCIALS
Employees:51-200
Revenue:$0M (Pre-commercial, development stage)
Founded:2017
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$181M
Investors:RA Capital Management, BVF Partners, EcoR1, Janus Henderson Investors, Hartford Hospital, Citadel, Orbimed, Samsara BioCapital, Avalon Ventures, Logos
STOCK
Exchange:NASDAQ
Ticker:JANX
Market Cap:$0.92B
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1b
Modalities:Bispecific antibodies, T cell engagers, mAb, Cell immunotherapy
Active Trials:3
Trial Phases:Phase 1: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Merck (MSD) - Strategic collaboration for TRACTr development targeting two undisclosed cancer targets, up to $500.5M per target in milestones plus royalties
COMPETITION
Position:Emerging
Competitors:Amgen, Regeneron, Johnson & Johnson, Candid Therapeutics, Clasp Therapeutics, Lava Therapeutics, Crescendo Biologics, Maverick Therapeutics +1 more
LEADERSHIP
Key Executives:
David Campbell, Ph.D. - President and CEO
Janeen Doyle, MBA - Chief Corporate and Business Development Officer
Ronald W. Barrett, Ph.D. - Board Chairperson
Natasha Hernday - Board Member
Eric Dobmeier - Board Member
Scientific Founders:David Campbell, Ph.D. (Founder)
Board Members:Ronald W. Barrett, Ph.D. (Chair), Natasha Hernday, Eric Dobmeier
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Janux Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.